Longeveron Inc Down 6.84% To $1.77 After Earnings

Revenues were downbeat at $0.00. Keep in mind that the revenues reported were on an adjusted basis, so they may not be directly comparable to estimates and prior periods.

The stock is down 6.84% to $1.77 after the report.

Longeveron Inc's profit margins maintained as both earnings and revenue declined at the same pace.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Bearish Sentiment score at the moment based on recent trading.

Longeveron Inc has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 5, putting Longeveron Inc in the bottom 25% of stocks. The firm was recently trading at a 52-week low of $1.5 on October 9, 2023 and set a 52-week high on January 27, 2023 at $4.58.

Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and Hypoplastic left heart syndrome (HLHS).